Fortress Biotech Inc (FBIO.OQ)
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|61||2013||Chairman of the Board, President, Chief Executive Officer|
|60||2014||Vice Chairman of the Board|
|55||2017||Chief Financial Officer|
|51||2014||Executive Vice Chairman - Strategic Development|
|40||2017||Executive Vice President|
- BRIEF-Mustang Bio's Mb-102 Car T Therapy Achieves Complete Response In Phase 1 Clinical Trial
- BRIEF-Fortress Biotech forms subsidiary Tamid Bio to develop novel aav gene therapies in Orphan Diseases
- BRIEF-Mustang Bio names new vice president of finance and corporate controller
- BRIEF-Fortress Biotech posts Q3 loss per share $0.67
- BRIEF-Fortress Biotech announces pricing of series a preferred stock offering